Related Experiment Video
Updated: Aug 29, 2025
Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
Antiviral strategies against human metapneumovirus: Targeting the fusion protein
Annelies Van Den Bergh1, Benjamin Bailly1, Patrice Guillon1
1Institute for Glycomics, Griffith University, Gold Coast, Queensland 4222, Australia.
Abstract:
Human metapneumoviruses have emerged in the past decades as an important global pathogen that causes severe upper and lower respiratory tract infections. Children under the age of 2, the elderly and immunocompromised individuals are more susceptible to HMPV infection than the general population due to their suboptimal immune system. Despite the recent discovery of HMPV as a novel important respiratory virus, reports have rapidly described its epidemiology, biology, and pathogenesis. However, progress is still to be made in the development of vaccines and drugs against HMPV infection as none are currently available. Herein, we discuss the importance of HMPV and review the reported strategies for anti-HMPV drug candidates. We also present the fusion protein as a promising antiviral drug target due to its multiple roles in the HMPV lifecycle. This key viral protein has previously been targeted by a range of inhibitors, which will be discussed as they represent opportunities for future drug design.
Insights
Human metapneumovirus (HMPV) causes severe respiratory infections, particularly in vulnerable groups. Research is ongoing to develop antiviral drugs targeting the HMPV fusion protein, a promising candidate for future therapies.
Area of Science:
- Virology
- Infectious Diseases
- Drug Discovery
Background:
- Human metapneumovirus (HMPV) is a significant global respiratory pathogen.
- HMPV disproportionately affects young children, the elderly, and immunocompromised individuals.
Purpose of the Study:
- To review the importance of HMPV and current strategies for anti-HMPV drug development.
- To highlight the HMPV fusion protein as a key target for antiviral therapies.
Main Methods:
- Review of existing literature on HMPV epidemiology, biology, and pathogenesis.
- Analysis of reported anti-HMPV drug candidates and their mechanisms.
- Focus on inhibitors targeting the HMPV fusion protein.
Main Results:
- HMPV remains a critical public health concern with no available vaccines or drugs.
- The HMPV fusion protein plays multiple roles in the viral lifecycle, making it an attractive target.
- Previous research has identified various inhibitors targeting the fusion protein.
Conclusions:
- The HMPV fusion protein represents a promising target for novel antiviral drug design.
- Further development of fusion protein inhibitors could lead to effective treatments for HMPV infections.
